$TKNO News
Last published 1w ago
- 1w agoTKNOAlpha Teknova, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoTKNOTeknova Reports Third Quarter 2026 Financial ResultsGlobeNewswireThird quarter 2026 total revenue was $12.7 million, up 22% over the same quarter prior yearCompany raises 2026 revenue guidance to $46-48 millionStrengthened balance sheet with $46 million public equity offering
- 3w agoTKNOTeknova to Report Third Quarter 2026 Financial Results on November 4, 2026GlobeNewswireHOLLISTER, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 3w agoTKNOTeknova Announces Pricing of $40 Million Public Offering of Common StockGlobeNewswireHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 3w agoTKNOTeknova Announces Proposed Public Offering of Common StockGlobeNewswireHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 3w agoTKNOTeknova Announces Preliminary Third Quarter Financial ResultsGlobeNewswireHOLLISTER, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 1mo agoTKNOTeknova Expands Custom Manufacturing with Fill-Tek™ Dispensing System for Flexible Single-Use Bag FillingGlobeNewswireHOLLISTER, Calif., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 2mo agoTKNOALPHA TEKNOVA INC. (TKNO) - ALPHA TEKNOVA INCEarnings Call TranscriptsGood afternoon, and welcome to the Sidonian Company August Investor Conference. The next company to present is Technova. With us, we have their CFO, Matt Wall. As always, this will be a 30-minute presentation. There shou
- 3mo agoTKNOTeknova Reports Second Quarter 2026 Financial ResultsGlobeNewswireSecond quarter 2026 total revenue was $12.2 million, up 18% over the same quarter prior yearCompany raises 2026 revenue guidance to $45-47 millionLaunched proprietary AI-powered Build-Tek™ custom order configurator,
- 3mo agoTKNOTeknova Launches Build-Tek™, a Proprietary AI Reagent Assistant That Allows Customers to Configure Complex Custom Product Requests in MinutesGlobeNewswireHOLLISTER, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 3mo agoTKNOTeknova to Report Second Quarter 2026 Financial Results on August 5, 2026GlobeNewswireHOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel
- 6mo agoTKNOTeknova First Quarter 2026 Financial Results - ALPHA TEKNOVA INCEarnings Call TranscriptsHello, and welcome to TechNobo first quarter 2026 financial results. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask the que
- 6mo agoTKNOTeknova Reports First Quarter 2026 Financial ResultsGlobeNewswireFirst quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior yearCompany reaffirms 2026 revenue guidance of $42-44 million HOLLISTER, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova,
- 6mo agoTKNOTeknova to Report First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireHOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 8mo agoTKNOTeknova Fourth Quarter 2025 Financial Results - ALPHA TEKNOVA INCEarnings Call TranscriptsGood day, and welcome to TechNova's fourth quarter and full year 2025 financial results call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer
- 8mo agoTKNOTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireFull year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidanceFourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior yearCompany provides 2026 revenue
- 9mo agoTKNOTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026GlobeNewswireHOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 1y agoTKNOTeknova Reports Third Quarter 2025 Financial ResultsGlobeNewswireThird quarter 2025 total revenue was $10.5 million, up 9% from prior yearAchieves five consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif.,
- 1y agoTKNOTeknova to Report Third Quarter 2025 Financial Results on November 6, 2025GlobeNewswireHOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 1y agoTKNOAlpha Teknova, Inc. (TKNO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoTKNOTeknova Reports Second Quarter 2025 Financial ResultsGlobeNewswireSecond quarter 2025 total revenue was $10.3 million, up 7% from prior yearAchieves four consecutive quarters of year-over-year revenue growthCompany reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif.,
- 1y agoTKNOTeknova to Report Second Quarter 2025 Financial Results on August 7, 2025GlobeNewswireHOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 1y agoTKNOTeknova Reports First Quarter 2025 Financial ResultsGlobeNewswireFirst quarter 2025 total revenue was $9.8 million, up 5% from prior yearCompany introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc.Company reaffirms 2025 revenue
- 1y agoTKNOTeknova to Report First Quarter 2025 Financial Results on May 8, 2025GlobeNewswireHOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 1y agoTKNOTeknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell TherapiesGlobeNewswireHOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for
- 1y agoTKNOTeknova and Pluristyx Announce Collaboration to Streamline the Manufacture of Next-Generation Cell TherapiesGlobeNewswireHOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize
- 1y agoTKNOTeknova Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewswireFull year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue
- 1y agoTKNOTeknova to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025GlobeNewswireHOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOAlpha Teknova, Inc. (TKNO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTKNOTeknova Reports Third Quarter 2024 Financial ResultsGlobeNewswireThird quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38
- 2y agoTKNOTeknova to Report Third Quarter 2024 Financial Results on November 7, 2024GlobeNewswireHOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOAlpha Teknova, Inc. (TKNO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTKNOTeknova Reports Second Quarter 2024 Financial ResultsGlobeNewswireSecond quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms
- 2y agoTKNOTeknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy DevelopmentGlobeNewswireExpress-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time New manufacturing grade, RUO+, provides a seamless and cost-effective
- 2y agoTKNOTeknova to Report Second Quarter 2024 Financial Results on August 13, 2024GlobeNewswireHOLLISTER, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOTeknova Announces Closing of $15.4 Million Private PlacementGlobeNewswireHOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOTeknova Announces $15.4 Million Private PlacementGlobeNewswireHOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOTeknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 ResultsGlobeNewswireSecond quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova"
- 2y agoTKNOAlpha Teknova, Inc. (TKNO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTKNOTeknova Reports First Quarter 2024 Financial ResultsGlobeNewswireFirst quarter 2024 total revenue was $9.3 million, up 2% from prior yearLaunch of Build-Tek™ Custom ConfiguratorCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 (GLOBE
- 2y agoTKNOTeknova Launches Proprietary Build-Tek™ Solutions Custom Configurator and Latest AAV-Tek™ Product to Further Accelerate Novel Therapy DevelopmentGlobeNewswireFirst-of-its-kind custom configurator – available today – gives scientists access to high quality, customizable buffers in small volumes for use in early-stage experiments, all with exceptionally short turnaround times
- 2y agoTKNOTeknova to Report First Quarter 2024 Financial Results on May 13, 2024GlobeNewswireHOLLISTER, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 2y agoTKNOAlpha Teknova, Inc. (TKNO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoTKNOTeknova Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireFull year 2023 total revenue was $36.7 million, down 11% year-over-yearAchieved 36% annual growth in the number of Clinical Solutions customers in 2023Company provides 2024 revenue guidance of $35-38 million HOLLISTER,
- 3y agoTKNOTeknova Reports Third Quarter 2023 Financial ResultsGlobeNewswireRaised $22.9 million of equity capital, paid down $10.0 million of long-term debtThird quarter 2023 total revenue was $8.2 million, down 24% from prior yearExpect 2023 revenue at the low end of previously announced
- 3y agoTKNOTeknova to Report Third Quarter 2023 Financial Results on November 9, 2023GlobeNewswireHOLLISTER, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies,
- 3y agoTKNOTeknova Launches Latest Proprietary AAV-Tek™ Product and End-to-End Plasmid Workflow Solutions to Streamline Therapeutic Process DevelopmentGlobeNewswireHOLLISTER, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel
- 3y agoTKNOTeknova Announces Closing of $22.9 Million Concurrent Registered Direct Offering and Private Placement and Amends Credit FacilityGlobeNewswireHOLLISTER, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies,
- 3y agoTKNOTeknova Announces Up to $22.9 Million Concurrent Registered Direct Offering and Private PlacementGlobeNewswireHOLLISTER, Calif., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies,
- 3y agoTKNOTeknova Announces New Board Member, Martha J. DemskiGlobeNewswireHOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies,